AI predicts lung boost from obesity drugs
NCT ID NCT07663591
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This study looks at how incretin-based therapies (like GLP-1 drugs used for weight loss) affect breathing in people with obesity. Researchers will analyze data from 48 adults aged 25-60 with a BMI of 30 or higher. They will use machine learning to find patterns that predict improvements in lung function and respiratory muscle strength.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY (BMI>30) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
incretin-based therapy (a class of diabetes/weight-loss drugs like GLP-1 agonists)
What this could lead to
If successful, this could help doctors predict which patients with obesity will see the most improvement in breathing after incretin-based therapy.
What could go wrong
This is a small, early-stage analysis of existing data, not a new treatment trial. Results may not apply to everyone, and the study hasn't started recruiting yet.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.